

1 **High sensitivity of a novel rapid test for the diagnosis of clinical and subclinical *Plasmodium***
2 ***falciparum* infections in a high transmission setting in Burundi**

3
4 David Niyukuri¹, Denis Sinzinkayo^{1,2}, Emma Troth³, Colins Oduma⁴, Mediatrice Barengayabo¹, Mireille
5 Ndereyimana¹, Aurel Holzschuh³, Claudia A. Vera-Arias³, Yilekal Gebre³, Kingsley Badu⁵, Joseph
6 Nyandwi^{1,6}, Dismas Baza⁷, Elizabeth Juma⁸, Cristian Koepfli^{3*}

7
8 ¹ Doctoral School, University of Burundi, Bujumbura, Burundi

9 ² National Malaria Control Program, Bujumbura, Burundi

10 ³ Eck Institute for Global Health and Department of Biological Sciences, University of Notre Dame, Notre
11 Dame, USA

12 ⁴ Kenya Medical Research Institute, Kisumu, Kenya

13 ⁵ Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

14 ⁶ National Institute of Public Health, Bujumbura, Burundi

15 ⁷ WHO Country office, Bujumbura, Burundi

16 ⁸ WHO African Region, Accra, Ghana

17

18 *Corresponding author: ckoepfli@nd.edu

19

20

21 **Abstract**

22 Rapid diagnostic tests (RDTs) are a key tool for the diagnosis of malaria infections among febrile and
23 subclinical individuals. Low-density infections, and deletions of the *P. falciparum* *hrp2/3* genes (encoding
24 for the HRP2 and HRP3 proteins detected by many RDTs) present challenges for RDT-based diagnosis.
25 The novel Rapigen Biocredit three-band *Plasmodium falciparum* HRP2/LDH RDT was evaluated among
26 444 febrile and 468 subclinical individuals in a high transmission setting in Burundi. Results were
27 compared to the AccessBio CareStart HRP2 RDT, and qPCR with a sensitivity of <0.1 parasites/ μ L blood.
28 Sensitivity among clinical patients was 80.0% (250/313, either of HRP2/LDH positive), compared to
29 73.2% (229/313) for CareStart ($P=0.048$). Among subclinical infections, sensitivity was 72.3% (162/224)
30 compared to 58.5% (131/224) for CareStart ($P=0.003$), and reached 88.3% (53/60) in children <15 years.
31 No (0/362) *hrp2* and 2/366 *hrp3* deletions were observed. In conclusion, the novel RDT showed improved
32 sensitivity for the diagnosis of *P. falciparum*.

33

34 Introduction

35

36 Accurate diagnosis and treatment of malaria infections is a key pillar for control. Over the last decade,
37 rapid diagnostic tests (RDTs) have become widely used for diagnosis. RDTs are lateral flow devices that
38 detect parasite-specific proteins by immunohistochemistry. No laboratory infrastructure is required for
39 RDT use, they can be used with minimal training, and results are available within 10-20 minutes [1, 2].
40 The sensitivity of RDTs for the diagnosis of clinical cases is similar or better than light microscopy, the
41 only other method for diagnosis in health centers. RDTs are used in many peripheral health centers
42 where microscopy is not available, and by community health workers. In 2020, nearly 300 million RDTs
43 were used by malaria control programs [3].

44

45 In addition to clinical infections diagnosed at health centers, subclinical infections present a major
46 challenge for transmission. While not causing febrile illness, subclinical infections can result in more
47 subtle health impacts, e.g. anemia [4]. Using different approaches, several studies found that over 50% of
48 transmission originates from asymptomatic infections [5-7]. A study conducted in western Kenya
49 estimated 95% of transmission stemming from subclinical carriers [8]. RDTs are the key diagnostic tool
50 for strategies to target the subclinical reservoir, for example through active [9, 10] or reactive case
51 detection [11, 12],

52

53 Among clinical and subclinical infections, a proportion of infections are below the limit of detection of
54 RDTs and remain untreated. These untreated infections might result in extended periods of illness, and
55 sustain onward transmission. More sensitive RDTs might be needed to achieve further gains in malaria
56 control and elimination.

57

58 Apart from low parasite density, deletions of the *hrp2* and *hrp3* genes are a threat to diagnosis by RDT.
59 The most sensitive RDTs for *P. falciparum* detect the HRP2 and HRP3 proteins. Deletions of these genes
60 have been initially described in Peru [13] and later in multiple countries, and result in false-negative RDTs
61 even when parasite density is high. In Africa, deletions are particularly prevalent around the Horn of Africa

62 [14-16], and have been described in multiple other countries, e.g. the Democratic Republic of Congo [17],
63 and Ghana [18]. Alternative diagnostic targets include Plasmodium Lactate Dehydrogenase (pLDH) or
64 Aldolase. These proteins are essential and thus genes cannot be deleted, but sensitivity of diagnosis is
65 lower compared to HRP2 [19]. The WHO recommends regular surveillance of *hrp2/hrp3* deletion to select
66 the optimal tool for diagnosis [20].

67
68 Burundi experiences among the highest levels of malaria transmission globally [21, 22]. In contrast to the
69 trend in many other countries in sub-Saharan Africa, the number of cases has increased in the last two
70 decades [22]. The increase was observed despite an increase in the number of health centers offering
71 diagnosis and treatment, and increase in testing, and roll-out of interventions such as bed nets and indoor
72 residual spraying (IRS) [22]. To understand the benefit a novel, highly sensitive RDT, suspected febrile
73 cases presenting to a health center, and subclinical community members were tested by the novel RDT,
74 an established RDT, and results compared to highly sensitive qPCR. *P. falciparum* positive infections
75 were typed for *hrp2* and *hrp3* deletions.

76

77

78 **Study Population and Methods**

79

80 **Ethical approval**

81 Informed written consent was collected from each individual, or, in the case of minors, from the legal
82 guardian prior to sample collection. This study was approved by the Comité National d'Ethique pour la
83 protection des êtres humains sujets de la recherche biomédicale et comportementale of Burundi
84 (approval no. CNE/03/2021), and the University of Notre Dame Institutional Review Board (approval no.
85 21-02-6446).

86

87 **Rapid diagnostic tests**

88 The Biocredit Malaria Ag Pf (pLDH/HRPII) RDT, manufactured by Rapigen, contains two test bands, one
89 for HRP2 and one for LDH, in addition to the control band. Plasmodium Lactate Dehydrogenase (pLDH)

90 is an enzyme of the glycolytic pathway and essential for the parasite. Histidine Rich Protein 2 and 3 are
91 highly expressed proteins. Their function is not well understood [2]. Deletions of the *hrp2* and *hrp3* genes
92 result in false-negative RDTs.

93 Given the separated HRP2 and LDH bands, the test can be used for surveillance of possible *hrp2*
94 deletion. Differences in sensitivity of HRP2 and LDH can be studied using a single test. This test meets
95 critical WHO criteria and is currently undergoing WHO prequalification [23].

96
97 As comparison, the AccessBio CareStart Malaria Pf (HRP2) RDT was used. This HRP2-based RDT has
98 been in use for approximately ten years [24-26]. It is the main RDT used by health systems in multiple
99 African countries [18, 27].

100

101 **Sample collection and RDT diagnosis**

102 Burundi experiences high, year-round transmission of *P. falciparum* malaria with moderate seasonality.
103 Samples were collected in Cibitoke Province in northwestern Burundi. Cibitoke Province borders Rwanda
104 and the Democratic Republic of Congo (DRC). Samples were collected during the dry, lower transmission
105 season in June 2021. Clinical samples were collected in health centers. All patients presenting for malaria
106 diagnosis were invited to join the study. Subclinical samples were collected on a market, with all
107 individuals present invited to join the study. Demographic data of study participants are given in Table 1.
108 Due to the convenience sampling strategy, the study population does not represent the general
109 population. Only 27/468 subclinical individuals were children below 5 years of age, and only 73/468 were
110 children aged 5-15 years. The majority of those sampled were female.

111

112

113

114

115

116

117

118

Clinical		N	Test positivity by qPCR		P	Test positivity by RDT		P	RDT sensitivity	P
Age group	0-5	158	62.0%	0.002	0.002	49.4%	<0.001	72.4%	<0.001	
	5-15	99	82.8%			86.9%		96.3%		
	>15	187	71.1%			58.3%		75.2%		
Gender	Male	181	67.4%	0.236	0.236	62.7%	0.514	82.0%	0.460	
	Female	263	72.6%			59.7%		78.5%		
Subclinical		N	Prevalence by qPCR		P	Prevalence by RDT		P	RDT sensitivity	P
Age group	0-5	27	51.8%	0.015	0.015	55.6%	<0.001	78.6%	0.003	
	5-15	73	63.0%			67.1%		91.3%		
	>15	368	44.7%			36.8%		66.5%		
Gender	Male	217	50.7%	0.272	0.272	39.6%	0.158	75.5%	0.303	
	Female	250	45.6%			46.1%		69.3%		

119

120 **Table 1:** Demographics of study population and risk factors for infection (by qPCR and RDT). For RDT data, results
 121 from the Biocredit test were included, with either band (HRP2 or LDH) positive counting as a positive test. Test
 122 positivity and prevalence by RDT includes individuals that were RDT positive but qPCR negative, resulting in higher
 123 test positivity or prevalence by RDT than qPCR in some groups. RDT sensitivity is calculated as proportion of RDT
 124 positive individuals among those positive by qPCR.

125

126 Approximately 200 μ L blood was collected by finger prick into EDTA tubes. Two RDTs were run on site.
 127 Remaining blood was stored at -20°C until DNA extraction.

128

129 ***P. falciparum* qPCR and *hrp2/3* deletion typing**

130 DNA was extracted using the Macherey-Nagel NucleoMag Blood 200 μ L kit according to manufacturer's
 131 instructions. This kit yields very high DNA recovery, resulting in a low limit of detection [28]. DNA was
 132 extracted from 200 μ L blood and eluted in 100 μ L elution buffer. qPCR was done in a total volume of 12
 133 μ L, including 2 μ L DNA, corresponding to 4 μ L blood. The *P. falciparum* varATS assay was used. This
 134 assay targets a multicopy gene that is present in approximately 60 copies per parasite, of which
 135 approximately 20 copies are amplified with the primers and probe used. It thus offers very high sensitivity
 136 of <0.1 parasites/ μ L blood [29]. For absolute quantification of parasite density, a standard curve derived
 137 from DNA from cultured 3D7 parasites and quantified by droplet digital PCR (ddPCR) was run along

138 samples. Samples positive for *P. falciparum* at a density of approximately >5 parasites/ μ L were typed for
139 *hrp2* and *hrp3* deletion by ddPCR [30].

140

141 Data analysis

142 As parasite density distributions were skewed, geometric mean densities are given whenever densities
143 are reported. To determine the limit of detection (LoD) of each RDT target, logistic regression analysis
144 was conducted. LoD was defined as the lowest parasite density where a qPCR-positive infection would
145 be detected with 95% probability. CI95 = 95% confidence interval.

146

147

148 Results

149 RDT sensitivity and specificity


150 444 febrile patients presenting to a health center were enrolled. By qPCR, *P. falciparum* positivity was
151 70.5% (313/444). Mean parasite density by qPCR was 727.4 parasites/ μ L (CI95: 405.9, 1303.6).
152 Counting either band (HRP2 or LDH) positive, the sensitivity of the Biocredit RDT was 79.9% (250/313 of
153 infections detected, Figure 1A, Table 2). 23 individuals tested positive by RDT, but negative by qPCR,
154 resulting in a specificity of 82.4%.

	LoD [parasites/ μ L]	Clinical		Subclinical	
		Sensitivity	Specificity	Sensitivity	Specificity
Biocredit any band	34	79.9%	82.4%	72.3%	84.4%
Biocredit HRP2	42	77.6%	90.1%	71.0%	88.1%
Biocredit LDH	290	71.9%	91.6%	50.0%	93.4%
CareStart HRP2	178	73.2%	96.2%	58.5%	93.4%

155

156 **Table 2:** Sensitivity, specificity, and limit of detection of RDTs.

157



158

159 **Figure 1:** Correspondence among qPCR, and different RDTs and RDT targets. For panel A, when either band on the
 160 Biocredit RDT was positive it was recorded as positive. Panel B includes false-positive RDTs that were negative by
 161 qPCR.

162


163 Among 468 subclinical individuals enrolled, 47.9% (224/468) were positive by qPCR. Mean parasite
 164 density was 22.9 parasites/ μ L (CI95: 13.1, 40.3). The sensitivity of the Biocredit test was 72.3% (162/238,
 165 Figure 1A, Table 2). 38 individuals were positive by RDT but negative by qPCR, resulting in a specificity
 166 of 84.4% (194/230).

167

168 The novel Biocredit RDT was compared against the CareStart RDT, an established product routinely
 169 used in multiple countries (Figure 1A). The CareStart RDT showed a sensitivity of 73.2% (229/313)
 170 among clinical individuals and thus was slightly less sensitive than the Biocredit RDT with a sensitivity of
 171 79.9% ($P < 0.001$, Table 2). Five individuals tested positive by CareStart RDT but negative by qPCR,
 172 resulting in a specificity of 96.2%. Among subclinical individuals, sensitivity of the CareStart was 58.5%
 173 (131/224), and thus substantially lower than the Biocredit at 72.3%. Specificity was 93.4% (228/244,
 174 $P < 0.001$, Table 2).

175

176 On the Biocredit RDT, the HRP2 band was more sensitive than the LDH band (Figure 1B). Among clinical
177 individuals, sensitivity of HRP2 was 77.6% (243/313), compared to 71.9% (225/313) for the LDH band
178 ($P < 0.001$, Table 2). Specificity was 90.1% (118/131) for HRP2, and 91.6% (120/131) for LDH (Table 2).
179 Among subclinical individuals, the difference in sensitivity between HRP2 and LDH was more pronounced
180 than among clinical infections. Sensitivity of HRP2 was 71.0% (159/224), compared to 50.0% (112/224)
181 for LDH ($P < 0.001$, Table 2). Specificity for HRP2 only was 88.1% (215/244), and for LDH only it was
182 93.4% (214/230, Table 2). Low correspondence between false-positive HRP2 and LDH bands was
183 observed. Among 61 false-positive RDTs (clinical and subclinical combined), only 8 were false-positive for
184 both targets, 34 were positive for HRP2 only, and 19 for LDH only.
185
186 The LoD, defined as the lowest parasite density that could be detected with 95% probability, was 34
187 parasites/ μ L (CI₉₅ 17, 82) for the Biocredit RDT (any band), 42 parasites/ μ L (CI₉₅ 22, 96) for the
188 Biocredit HRP2 band, 290 parasites/ μ L (CI₉₅ 159, 617) for the Biocredit LDH band, and 178 parasites/ μ L
189 (CI₉₅ 94, 399) for CareStart (Table 2, Figure 2).



190

191 **Figure 2:** Limit of Detection (LoD) of each RDT and RDT target in relation to parasite density. Parasite density (by
192 qPCR) of RDT positive and RDT negative samples is shown along the top and bottom X-axis. Shaded lines show
193 95% confidence intervals. A) Biocredit (any band) B) Biocredit HRP2 C) Biocredit LDH D) CareStart HRP2

194

195 ***hrp2/3* deletion typing**

196 362 *P. falciparum* positive samples were successfully typed for *hrp2* deletion, and 366 were successfully
197 typed for *hrp3* deletion. No *hrp2* deletions were observed. Two samples carried *hrp3* deletion, one each
198 collected from a clinical and subclinical patient. The subclinical individual was negative by all RDTs at a
199 density of 39 parasites/ μ L by ddPCR. The clinical individual was RDT positive at a density of 136,000
200 parasites/ μ L.

201

202 **Demographic risk factors for infection**

203 Prevalence of subclinical infection, and test positivity rate peaked in children aged 5 to 15 years, both by
204 qPCR and RDT (Table 1). Parasite densities decreased with age in clinical and subclinical infections
205 (clinical: 9.7% decrease per year, $P<0.001$; subclinical: 4.6% decrease per year, $P=0.003$). As a result,
206 RDT sensitivity tended to be higher in children than adults. Among clinical infections, sensitivity of the
207 Biocredit RDT (any band) was 83.3% (150/180) in children below 15 years compared to 75.2% (100/133)
208 in adults aged 15 and older ($P=0.076$). Among subclinical infections, sensitivity was 88.3% (53/61) in
209 children and 66.5% (109/164) in adults ($P=0.001$).

210

211 No significant differences were observed between men and women in prevalence by qPCR or RDT, or
212 RDT sensitivity (Table 1).

213

214

215 **Discussion**

216

217 This study found high sensitivity of a novel RDT for the diagnosis of *P. falciparum* infections in clinical and
218 subclinical individuals in highly endemic setting in Burundi. Using a highly sensitive qPCR with a limit of

219 detection of <0.1 parasites/ μ L blood as gold standard, the RDT detected 80% of clinical and 72% of
220 subclinical infections. The novel RDT performed substantially better compared to an established product
221 that is used by malaria control programs in multiple countries.

222
223 Children are at highest risk of severe malaria, and in high transmission settings they are an important
224 reservoir of transmission. The convenience sampling on a market resulted in an underrepresentation of
225 children among subclinical individuals, with only 21% (100/468) study participants being below 15 years
226 of age, compared to approximately 45% in the general population [31]. In the small group of 61 children
227 that were positive by qPCR, the Biocredit RDT detected 88% of infections. Testing a group with an age
228 distribution more representative of the general population, it is expected that the overall sensitivity of the
229 RDT would be even higher than the 72% measured in the present study.

230
231 Compared to the established CareStart RDT, the LoD (defined as the parasite density where the
232 probability of a positive RDT is 95%) of the Biocredit RDT was 5-fold lower. The LoD of the Biocredit
233 HRP2-band only was 4-fold lower compared to the CareStart RDT, and the LoD of the Biocredit LDH-
234 band only was moderately higher than the one of the CareStart. Of note, differences in the protocols used
235 for DNA extraction [28], and in the external standards used for qPCR [32], result in pronounced
236 differences in parasite quantification. Results from different studies are thus not directly comparable. We
237 extracted DNA from whole blood and used an extraction protocol that yielded fourfold more DNA than
238 another common protocol. Further, extraction from whole blood yielded tenfold more DNA than from DBS
239 [28]. Using these protocols resulted in high DNA recovery, and thus in higher LoDs.

240
241 No *hrp2* deletions were detected in the study population. Differences in the number of tests positive by
242 LDH and HRP2 are thus fully caused by differences in the LoD of these targets. On the Biocredit RDT,
243 HRP2 was substantially more sensitive than LDH. Where no deletions are present, HRP2-based RDTs
244 remain the most sensitive diagnostic target for RDTs. Among clinical infections, sensitivity of the Biocredit
245 LDH band was very similar to the AccessBio HRP2-based RDT (72% vs. 73%). Countries that switch to

246 non-HRP2-based RDTs due to high levels of deletion can expect similar sensitivity of diagnosis in clinical
247 settings using the new test as with previous HRP2-based RDTs.

248
249 A high rate of false-positive RDTs was observed, and consequently a relatively low specificity. Antigens
250 can persist after parasite clearance [33], though LDH levels were shown to follow parasite density closely
251 [33]. Antigens persisting after treatment were shown to be a major cause of false-positive RDTs [34].
252 Recent treatment was not assessed in this study, thus this factor could not be assessed as cause for
253 false-positive RDTs. False-positive RDTs can also be the result of non-*Plasmodium* infections [35, 36]
254 and non-infectious diseases [37]. Most false-positive Biocredit RDTs were positive by one target only,
255 either HRP2 or LDH. Using an RDT with two bands reduces specificity compared to a single-target test.

256
257 Half of the population in the study site in Burundi's north-west carried subclinical *P. falciparum* infections.
258 These individuals are expected to be an important source of transmission [5-8]. Interventions targeting
259 the asymptomatic reservoir might be needed to reduce transmission. The high sensitivity of the Biocredit
260 RDT to diagnose subclinical infections opens up new avenues for malaria control, e.g. through mass
261 screen and treat campaigns. Given the absence of *hrp2* deletions, HRP2-based diagnostic remains
262 appropriate in the site of the current study. Surveillance for *hrp2* and *hrp3* deletions will be required in
263 other sites across Burundi.

264
265 In conclusion, the Biocredit RDT offers high sensitivity for the diagnosis of clinical and subclinical
266 infections. Parasite density distributions differ across transmission intensities, and more subpatent
267 infections are generally observed as transmission declines [38, 39]. Studies in regions of medium and low
268 transmission will be required to determine sensitivity and specificity in these populations.

269

270 **Acknowledgements**

271 We thank all study participants and field teams.

272

273 **Funding**

274 This work was supported by the National Institutes of Health grant R21AI137891. The funders
275 had no role in study design, data analysis, decision to publish, or preparation of the manuscript.

276 **References**

- 277 1. World Health Organisation. How malaria RDTs work. Available from:
278 [https://www.who.int/teams/global-malaria-programme/case-management/diagnosis/rapid-](https://www.who.int/teams/global-malaria-programme/case-management/diagnosis/rapid-diagnostic-tests/how-malaria-rdts-work)
279 [diagnostic-tests/how-malaria-rdts-work](https://www.who.int/teams/global-malaria-programme/case-management/diagnosis/rapid-diagnostic-tests/how-malaria-rdts-work).
- 280 2. Poti KE, Sullivan DJ, Dondorp AM, Woodrow CJ. HRP2: Transforming Malaria Diagnosis,
281 but with Caveats. Trends Parasitol. 2020;36(2):112-26. Epub 2019/12/19. doi:
282 10.1016/j.pt.2019.12.004. PubMed PMID: 31848119.
- 283 3. World Health Organisation. World malaria report 2021. Geneva: 2021.
- 284 4. de Mast Q, Brouwers J, Syafruddin D, Bousema T, Baidjoe AY, de Groot PG, et al. Is
285 asymptomatic malaria really asymptomatic? Hematological, vascular and inflammatory effects
286 of asymptomatic malaria parasitemia. J Infection. 2015;71(5):587-96. doi:
287 10.1016/j.jinf.2015.08.005. PubMed PMID: WOS:000368479700011.
- 288 5. Goncalves BP, Kapulu MC, Sawa P, Guelbeogo WM, Tiono AB, Grignard L, et al.
289 Examining the human infectious reservoir for Plasmodium falciparum malaria in areas of
290 differing transmission intensity. Nat Commun. 2017;8(1):1133. Epub 2017/10/28. doi:
291 10.1038/s41467-017-01270-4. PubMed PMID: 29074880; PubMed Central PMCID:
292 PMC5658399.
- 293 6. Ouedraogo AL, Goncalves BP, Gneme A, Wenger EA, Guelbeogo MW, Ouedraogo A, et
294 al. Dynamics of the Human Infectious Reservoir for Malaria Determined by Mosquito Feeding
295 Assays and Ultrasensitive Malaria Diagnosis in Burkina Faso. J Infect Dis. 2016;213(1):90-9. Epub
296 2015/07/05. doi: 10.1093/infdis/jiv370. PubMed PMID: 26142435.

- 297 7. Tadesse FG, Slater HC, Chali W, Teelen K, Lanke K, Belachew M, et al. The Relative
298 Contribution of Symptomatic and Asymptomatic Plasmodium vivax and Plasmodium falciparum
299 Infections to the Infectious Reservoir in a Low-Endemic Setting in Ethiopia. Clin Infect Dis.
300 2018;66(12):1883-91. Epub 2018/01/06. doi: 10.1093/cid/cix1123. PubMed PMID: 29304258.
- 301 8. Sumner KM, Freedman E, Abel L, Obala A, Pence BW, Wesolowski A, et al. Genotyping
302 cognate Plasmodium falciparum in humans and mosquitoes to estimate onward transmission of
303 asymptomatic infections. Nat Commun. 2021;12(1):909. Epub 2021/02/12. doi:
304 10.1038/s41467-021-21269-2. PubMed PMID: 33568678; PubMed Central PMCID:
305 PMC7875998.
- 306 9. Scott CA, Yeshiwondim AK, Serda B, Guinovart C, Tesfay BH, Agmas A, et al. Mass testing
307 and treatment for malaria in low transmission areas in Amhara Region, Ethiopia. Malar J.
308 2016;15:305. Epub 2016/06/04. doi: 10.1186/s12936-016-1333-3. PubMed PMID: 27255330;
309 PubMed Central PMCID: PMC4890322.
- 310 10. Samuels AM, Odero NA, Odongo W, Otieno K, Were V, Shi YP, et al. Impact of
311 Community-Based Mass Testing and Treatment on Malaria Infection Prevalence in a High-
312 Transmission Area of Western Kenya: A Cluster Randomized Controlled Trial. Clin Infect Dis.
313 2021;72(11):1927-35. Epub 2020/04/24. doi: 10.1093/cid/ciaa471. PubMed PMID: 32324850.
- 314 11. Stuck L, Fakhri BS, Al-Mafazy AH, Hofmann NE, Holzschuh A, Grossenbacher B, et al.
315 Malaria infection prevalence and sensitivity of reactive case detection in Zanzibar. Int J Infect
316 Dis. 2020;97:337-46. Epub 2020/06/14. doi: 10.1016/j.ijid.2020.06.017. PubMed PMID:
317 32534138.

- 318 12. Searle KM, Katowa B, Musonda M, Pringle JC, Hamapumbu H, Matoba J, et al. Sustained
319 Malaria Transmission despite Reactive Screen-and-Treat in a Low-Transmission Area of
320 Southern Zambia. *Am J Trop Med Hyg.* 2020;104(2):671-9. Epub 2020/11/26. doi:
321 10.4269/ajtmh.20-0947. PubMed PMID: 33236715; PubMed Central PMCID: PMC7866307.
- 322 13. Gamboa D, Ho MF, Bendezu J, Torres K, Chiodini PL, Barnwell JW, et al. A large
323 proportion of *P. falciparum* isolates in the Amazon region of Peru lack *pfhrp2* and *pfhrp3*:
324 implications for malaria rapid diagnostic tests. *PLoS One.* 2010;5(1):e8091. Epub 2010/01/30.
325 doi: 10.1371/journal.pone.0008091. PubMed PMID: 20111602; PubMed Central PMCID:
326 PMC2810332.
- 327 14. Berhane A, Anderson K, Mihreteab S, Gresty K, Rogier E, Mohamed S, et al. Major Threat
328 to Malaria Control Programs by *Plasmodium falciparum* Lacking Histidine-Rich Protein 2,
329 Eritrea. *Emerg Infect Dis.* 2018;24(3):462-70. Epub 2018/02/21. doi: 10.3201/eid2403.171723.
330 PubMed PMID: 29460730; PubMed Central PMCID: PMC5823352.
- 331 15. Golassa L, Messele A, Amambua-Ngwa A, Swedberg G. High prevalence and extended
332 deletions in *Plasmodium falciparum* *hrp2/3* genomic loci in Ethiopia. *PLoS One.*
333 2020;15(11):e0241807. Epub 2020/11/06. doi: 10.1371/journal.pone.0241807. PubMed PMID:
334 33152025; PubMed Central PMCID: PMC7644029 adherence to PLOS ONE policies on data
335 or materials sharing.
- 336 16. Iriart X, Menard S, Chauvin P, Mohamed HS, Charpentier E, Mohamed MA, et al.
337 Misdiagnosis of imported *falciparum* malaria from African areas due to an increased prevalence
338 of *pfhrp2/pfhrp3* gene deletion: the Djibouti case. *Emerg Microbes Infect.* 2020;9(1):1984-7.

- 339 Epub 2020/09/02. doi: 10.1080/22221751.2020.1815590. PubMed PMID: 32869688; PubMed
340 Central PMCID: PMCPMC7534257.
- 341 17. Parr JB, Verity R, Doctor SM, Janko M, Carey-Ewend K, Turman BJ, et al. Pfhrrp2-Deleted
342 Plasmodium falciparum Parasites in the Democratic Republic of the Congo: A National Cross-
343 sectional Survey. J Infect Dis. 2016. doi: 10.1093/infdis/jiw538. PubMed PMID: 28177502.
- 344 18. Amoah LE, Abankwa J, Oppong A. Plasmodium falciparum histidine rich protein-2
345 diversity and the implications for PfHRP 2: based malaria rapid diagnostic tests in Ghana. Malar
346 J. 2016;15:101. Epub 2016/02/20. doi: 10.1186/s12936-016-1159-z. PubMed PMID: 26891848;
347 PubMed Central PMCID: PMCPMC4759916.
- 348 19. Li B, Sun Z, Li X, Li X, Wang H, Chen W, et al. Performance of pfHRP2 versus pLDH
349 antigen rapid diagnostic tests for the detection of Plasmodium falciparum: a systematic review
350 and meta-analysis. Arch Med Sci. 2017;13(3):541-9. Epub 2017/05/17. doi:
351 10.5114/aoms.2017.67279. PubMed PMID: 28507567; PubMed Central PMCID:
352 PMCPMC5420633.
- 353 20. World Health Organisation. Response plan to *pfhrp2* gene deletions. Geneva: 2019.
- 354 21. Lok P, Dijk S. Malaria outbreak in Burundi reaches epidemic levels with 5.7 million
355 infected this year. BMJ. 2019;366:l5104. Epub 2019/08/11. doi: 10.1136/bmj.l5104. PubMed
356 PMID: 31399412.
- 357 22. Sinzinkayo D, Baza D, Gnanguenon V, Koepfli C. The lead-up to epidemic transmission:
358 malaria trends and control interventions in Burundi 2000 to 2019. Malar J. 2021;20(1):298.
359 Epub 2021/07/04. doi: 10.1186/s12936-021-03830-y. PubMed PMID: 34215270; PubMed
360 Central PMCID: PMCPMC8249825.

- 361 23. World Health Organisation. Selecting and procuring malaria RDTs 2022 [cited 2022 April
362 12]. Available from: [https://www.who.int/teams/global-malaria-programme/case-](https://www.who.int/teams/global-malaria-programme/case-management/diagnosis/rapid-diagnostic-tests/selection-and-procurement)
363 [management/diagnosis/rapid-diagnostic-tests/selection-and-procurement](https://www.who.int/teams/global-malaria-programme/case-management/diagnosis/rapid-diagnostic-tests/selection-and-procurement).
- 364 24. Maltha J, Gillet P, Bottieau E, Cnops L, van Esbroeck M, Jacobs J. Evaluation of a rapid
365 diagnostic test (CareStart Malaria HRP-2/pLDH (Pf/pan) Combo Test) for the diagnosis of
366 malaria in a reference setting. *Malar J.* 2010;9:171. Epub 2010/06/23. doi: 10.1186/1475-2875-
367 9-171. PubMed PMID: 20565816; PubMed Central PMCID: PMCPMC2906498.
- 368 25. Moges B, Amare B, Belyhun Y, Tekeste Z, Gizachew M, Workineh M, et al. Comparison of
369 CareStart HRP2/pLDH COMBO rapid malaria test with light microscopy in north-west Ethiopia.
370 *Malar J.* 2012;11:234. Epub 2012/07/24. doi: 10.1186/1475-2875-11-234. PubMed PMID:
371 22818643; PubMed Central PMCID: PMCPMC3411439.
- 372 26. World Health Organisation. Malaria rapid diagnostic test performance: results of WHO
373 product testing of malaria RDTs: round 8 (2016–2018). Geneva: 2018 978-92-4-151496-5.
- 374 27. Teh RN, Sumbele IUN, Asoba Nkeudem G, Meduke DN, Ojong ST, Kimbi HK. Concurrence
375 of CareStart Malaria HRP2 RDT with microscopy in population screening for Plasmodium
376 falciparum infection in the Mount Cameroon area: predictors for RDT positivity. *Trop Med*
377 *Health.* 2019;47:17. Epub 2019/03/15. doi: 10.1186/s41182-019-0145-x. PubMed PMID:
378 30867636; PubMed Central PMCID: PMCPMC6397448.
- 379 28. Holzschuh A, Koepfli C. Tenfold difference in DNA recovery rate: systematic comparison
380 of whole blood vs. dried blood spot sample collection for malaria molecular surveillance. *Malar*
381 *J.* 2022;21(1):88. Epub 2022/03/17. doi: 10.1186/s12936-022-04122-9. PubMed PMID:
382 35292038.

- 383 29. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive
384 detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS
385 Med. 2015;12(3):e1001788. Epub 2015/03/04. doi: 10.1371/journal.pmed.1001788. PubMed
386 PMID: 25734259; PubMed Central PMCID: PMC4348198.
- 387 30. Vera-Arias CA, Holzschuh A, Oduma CO, Badu K, Abdul-Hakim M, Yukich J, et al.
388 Plasmodium falciparum hrp2 and hrp3 gene deletion status in Africa and South America by
389 highly sensitive and specific digital PCR. 2021. doi: 10.1101/2021.06.01.21258117.
- 390 31. United Nations Department of Economic and Social Affairs PD. World Population
391 Prospects 2019, Volume II: Demographic Profiles: Burundi 2019. Available from:
392 [https://population.un.org/wpp/Graphs/1 Demographic%20Profiles/Burundi.pdf](https://population.un.org/wpp/Graphs/1%20Demographic%20Profiles/Burundi.pdf).
- 393 32. Koepfli C, Nguitragool W, Hofmann NE, Robinson LJ, Ome-Kaius M, Sattabongkot J, et al.
394 Sensitive and accurate quantification of human malaria parasites using droplet digital PCR
395 (ddPCR). Sci Rep. 2016;6:39183. Epub 2016/12/17. doi: 10.1038/srep39183. PubMed PMID:
396 27982132; PubMed Central PMCID: PMC5159915.
- 397 33. Jang IK, Tyler A, Lyman C, Kahn M, Kalnoky M, Rek JC, et al. Simultaneous Quantification
398 of Plasmodium Antigens and Host Factor C-Reactive Protein in Asymptomatic Individuals with
399 Confirmed Malaria by Use of a Novel Multiplex Immunoassay. J Clin Microbiol. 2019;57(1). Epub
400 2018/11/09. doi: 10.1128/JCM.00948-18. PubMed PMID: 30404944; PubMed Central PMCID:
401 PMC6322473.
- 402 34. Hosch S, Yoboue CA, Donfack OT, Guirou EA, Dangy JP, Mpina M, et al. Analysis of
403 nucleic acids extracted from rapid diagnostic tests reveals a significant proportion of false
404 positive test results associated with recent malaria treatment. Malar J. 2022;21(1):23. Epub

- 405 2022/01/26. doi: 10.1186/s12936-022-04043-7. PubMed PMID: 35073934; PubMed Central
406 PMCID: PMCPMC8785039.
- 407 35. Meatherall B, Preston K, Pillai DR. False positive malaria rapid diagnostic test in
408 returning traveler with typhoid fever. *BMC Infect Dis.* 2014;14:377. Epub 2014/07/10. doi:
409 10.1186/1471-2334-14-377. PubMed PMID: 25005493; PubMed Central PMCID:
410 PMCPMC4094604.
- 411 36. Gatton ML, Ciketic S, Barnwell JW, Cheng Q, Chiodini PL, Incardona S, et al. An
412 assessment of false positive rates for malaria rapid diagnostic tests caused by non-Plasmodium
413 infectious agents and immunological factors. *PLoS One.* 2018;13(5):e0197395. Epub
414 2018/05/15. doi: 10.1371/journal.pone.0197395. PubMed PMID: 29758050; PubMed Central
415 PMCID: PMCPMC5951549.
- 416 37. Lee JH, Jang JW, Cho CH, Kim JY, Han ET, Yun SG, et al. False-positive results for rapid
417 diagnostic tests for malaria in patients with rheumatoid factor. *J Clin Microbiol.*
418 2014;52(10):3784-7. Epub 2014/07/25. doi: 10.1128/JCM.01797-14. PubMed PMID: 25056333;
419 PubMed Central PMCID: PMCPMC4187788.
- 420 38. Bousema T, Okell L, Felger I, Drakeley C. Asymptomatic malaria infections: detectability,
421 transmissibility and public health relevance. *Nat Rev Microbiol.* 2014;12(12):833-40. doi:
422 10.1038/nrmicro3364. PubMed PMID: 25329408.
- 423 39. Koepfli C, Ome-Kaius M, Jally S, Malau E, Maripal S, Ginny J, et al. Sustained Malaria
424 Control Over an 8-Year Period in Papua New Guinea: The Challenge of Low-Density
425 Asymptomatic Plasmodium Infections. *J Infect Dis.* 2017;216(11):1434-43. Epub 2017/10/14.

426 doi: 10.1093/infdis/jix507. PubMed PMID: 29029179; PubMed Central PMCID:

427 PMCPMC5853328.

428